The major sources of IL-6 in CRC are tumor-associated mesenchymal stem cells, macrophages and colon cancer-associated stromal fibroblasts. TLR1,7,8 inhibition ultimately leads to cessation of Epithelial to Leucocytic transition. Here, IL6 is linked to neoplasm.